Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 24, 2026 /PRNewswire/ — Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phase 1b KOANEWA trial evaluating CTx1000, an investigational genetic medicine targeting pathological forms of the […]